Page 71 - Read Online

Rosenzweig et al. J Cancer Metastasis Treat 2022;8:46 https://dx.doi.org/10.20517/2394-4722.2022.58 Page 9 of 9

Res 2018;24:737-43. DOI PubMed
35. Douglas JE, Liu S, Ma J, et al. PIONEER-panc: a platform trial for phase II randomized investigations of new and emerging therapies
for localized pancreatic cancer. BMC Cancer 2022;22:14. DOI PubMed PMC
36. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
DOI PubMed
37. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in
patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7. DOI PubMed
38. Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer:
systematic review and still-open questions. Cancers 2021;13:3119. DOI PubMed PMC